In an earlier study, approximately 40% of patients with previously treated NSCLC having best overall response (BOR) of partial response (PR) or complete response (CR) to PD-1 axis inhibitor therapy showed sustained response after follow-up of at least 2 years [10]. Here, PDCD1 is linked to non-small cell lung carcinoma.